Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company focused on developing innovative and proprietary medical devices and software, has created two devices designed to disrupt the EEG market. The NeuroCap(TM) and NeuroEEG(TM) offer cost-effective, disposable substitutes that help improve patient’s access to neurological care. The company is also helping improve the quality of care and solutions that practices can offer their patients.
An example of the impact of the device can be seen through Bergen Neurology Consultants, a premier provider of neurological care (https://ibn.fm/6BVN6). Bergen Neurology wanted to offer its patients ambulatory EEGs. The problem is that strict Medicare regulations required a routine EEG first. Bergen Neurology’s offices were not set up to provide the traditional in-office EEGs that would make the ambulatory ones “medically necessary” for the insurance companies.
The company discovered an optimal solution in the NeuroCap and NeuroEEG. Through its wholly owned subsidiary, MemoryMD Inc., BRSF was able to help Bergen Neurology Consultants streamline its practice, recoup revenue and improve patient care.
Because of their size and ease of use, the NeuroCap and NeuroEEG allowed Bergen Neurology to implement in-office EEGs within a week. One problem with traditional EEGs is that administering and monitoring requires an EEG technician. Within an hour, all of Bergen’s six medical assistants were trained in how to administer and monitor the BRSF EEG devices. Workers who typically are involved in patient scheduling and administrative duties were allocated to this vital task with minimal training.
This meant that more staff could administer the in-office EEGs allowing the practice to schedule them more often. The time it also took to use the NeuroCap and NeuroEEG decreased from one hour to 40 minutes, allowing for more tests to be scheduled. In addition, the original problem of reimbursement from insurance companies was resolved.
Brain Scientific is working hard to disrupt the EEG industry and provide solutions that make neurological care more accessible. The company’s work with Bergen Neurology is an example of how BRSF is establishing a new innovative norm for clinicians.
For more information, visit the company’s website at www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology…
Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across…
A survey that was conducted toward the end of last year by Gallup and West…
Soligenix reports clinical update centered on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin…
Lung cancer is the leading cause of cancer-linked fatalities among men and women, and survival beyond five…
Oncotelic Therapeutics has recently entered a strategic partnership with TechForce Robotics to commercialize a PDAOAI-enhanced,…